Long Non-Coding RNA as Potential Biomarker for Prostate Cancer: Is It Making a Difference?

Int J Environ Res Public Health. 2017 Mar 7;14(3):270. doi: 10.3390/ijerph14030270.

Abstract

Whole genome transcriptomic analyses have identified numerous long non-coding RNA (lncRNA) transcripts that are increasingly implicated in cancer biology. LncRNAs are found to promote essential cancer cell functions such as proliferation, invasion, and metastasis, with the potential to serve as novel biomarkers of various cancers and to further reveal uncharacterized aspects of tumor biology. However, the biological and molecular mechanisms as well as the clinical applications of lncRNAs in diverse diseases are not completely understood, and remain to be fully explored. LncRNAs may be critical players and regulators in prostate cancer carcinogenesis and progression, and could serve as potential biomarkers for prostate cancer. This review focuses on lncRNA biomarkers that are already available for clinical use and provides an overview of lncRNA biomarkers that are under investigation for clinical development in prostate cancer.

Keywords: PCA3; biomarkers; lncRNAs; prostate cancer.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor
  • Disease Progression
  • Humans
  • Male
  • Prostatic Neoplasms / genetics*
  • RNA, Long Noncoding / genetics*

Substances

  • Biomarkers, Tumor
  • RNA, Long Noncoding